

Table 2.7. Prevalence of HPV DNA in case series of vulvar cancer (10 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Kiyabu <i>et al.</i> (1989), USA	E6 for HPV16 and HPV18	8	N=6 (75%)	N/A	N/A	N=6 (100%)	N=1 (16.7%)	N/A	N/A	N/A	N=1 (16.7%) (HPV16&18)	Formalin-fixed paraffin-embedded tissue samples.
Eliezri <i>et al.</i> (1990), USA	Slot Blot Hybridization and some ISH (HPV 6/11, 16/18, 31/33/35, 42/43/44, 45/56, 51/52)	26	N=16 (61.5%)	N/A	N/A	N=14 (87.5%)	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples. Some of the cases are in situ carcinomas.
Bloss <i>et al.</i> (1991), USA	SB (HPV6, 11, 16, 18 & 31) and E6/E7 primers	8 Bowenoid SCC	N=8 (100%)	N=2 (25%)	N=0 (0%)	N=8 (100%)	N=0 (0%)	N=0 (0%)	N/A	N=0 (0%)	N=2 (25%) (HPV6&16)	Frozen specimens.
		9 Simplex SCC	N=0 (0%)	N=0 (0%)		N=0 (0%)				N=0 (0%)	N=0 (0%)	
		1 Basaloid SCC	N=0 (0%)	N=0 (0%)		N=0 (0%)				N=0 (0%)	N=0 (0%)	
		3 Unespecific SCC	N=2 (66.7%)	N=0 (0%)		N=2 (100%)				N=0 (0%)	N=0 (0%)	
Toki <i>et al.</i> (1991), USA-Japan	ISH/SBH for HPV6, 11, 16 & 18	3 Warty SCC	N=3 (100%)	N=0 (0%)	N=0 (0%)	N=2 (66.7%)	N=1 (33.3%)	N/A	N/A	N/A	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		8 Basaloid SCC	N=6 (75%)	N=0 (0%)	N=0 (0%)	N=6 (100%)	N=1 (16.7%)				N=1 (16.7%) (HPV16&18)	
		19 Keratinizing SCC	N=4 (21%)	N=0 (0%)	N=0 (0%)	N=3 (75%)	N=1 (25%)				N=0 (0%)	
Hording <i>et al.</i> (1991), Denmark	E6/E7 for HPV16 type specific	24	N=14 (58.3%)	N=0 (0%)	N=0 (0%)	N=14 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Frozen specimens.
Nuovo <i>et al.</i> (1991), USA	SBH and probes for HPV6, 11, 16, 18, 31, 33 & 35	23	N=7 (30.4%)	N=0 (0%)	N=0 (0%)	N=4 (57.14%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=3 (42.8%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Park <i>et al.</i> (1991), New Zealand	ISH and PCR for HPV6, 11, 16 & 18	6 Warty/Basaloid	N=5 (83.3%)	N=0 (0%)	N=0 (0%)	N=5 (100%)	N=0 (0%)	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
Della Torre <i>et al.</i> (1992), Italy	SB (HPV6, 11, 16 & 18) and E5 (HPV6, 11) E7 (16 & 18)	9 ISCC	N=5 (55.6%)	N=0 (0%)	N=0 (0%)	N=4 (80%)	N=1 (20%)	N/A	N/A	N/A	N=0 (0%)	Frozen specimens.
		1 ISCC in BL (Buschke-Lowenstein)	N=1 (100%)	N=1 (100%)		N=0 (0%)	N=0 (0%)					
		1 Verrucous	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)					
Ogunbiyi <i>et al.</i> (1994), UK	E6/E7 primers for HPV16	33	N=25 (75.8%)	N/A	N/A	N=25 (100%)	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.

Table 2.7. Prevalence of HPV DNA in case series of vulvar cancer (10 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Ansink <i>et al.</i> (1994), The Netherlands	GP5/GP6, and HPV Type specific for 6/11, 13, 16, 18, 30, 31, 32, 33, 45, 51	60	N=19 (31.7%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
Lee <i>et al.</i> (1994), USA	MY09/11, GP5/GP6, Southern Blot and type-specific for HPV6, 11, 16, 18, 31	21	N=12 (57.14%)	N=0 (0%)	N=0 (0%)	N=10 (83.3%)	N=1 (8.3%)	N=0 (0%)	N=0 (0%)	N=1 (8.3%) (HPV16 related)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Hørding <i>et al.</i> (1994), Denmark	E6/E7 primers (6, 11, 16, 18, 33)	51 keratinizing (37 well differentiated, 10 moderately differentiated & 4 poorly differentiated)	N=2 (3.9%)	N=0 (0%)	N=0 (0%)	N=22 (91.7%)	N=0 (0%)	N/A	N=3 (12.5%)	N/A	N=1 (4.16%) (HPV16&33)	Formalin-fixed paraffin-embedded tissue samples. 38 patients had stage I, 31 patients stage II, 8 patients stage III & 1 patient stage IV. HPV DNA found in 81% of cancers with overlying VINIII, 9.3% of tissues with overlying VINI–II and 0% of tissues with adjacent lichen sclerosis. 12 patients (15%) also had a diagnosis of CIN at some time during life.
		17 warty	N=12 (70.6%)									
		10 basaloid	N=10 (100%)									
Tate <i>et al.</i> (1994), USA	MY09/11	13	N=7 (53.84%)	N=0 (0%)	N=0 (0%)	N=6 (85.7%)	N=0 (0%)	N=0 (0%)	N=1 (14.3%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Monk <i>et al.</i> (1995), USA	MY09/11, GP5/GP6, Southern Blot and type-specific for HPV6, 16, 18	31 Typical	N=12 (38.7%)	N=1 (3%)	N/A	N=27 (81.8%)	N=3 (9.1%)	N/A	N/A	N=2 (6.1%) (HPVx)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. 9 patients had a history of CIN and all vulvar cancers from these women contained HPV16 DNA. 3 other patients were immunosuppressed.
		13 Basaloid	N=12 (92.3%)									
		8 Warty	N=8 (100%)									
		1 Verrucous	N=1 (100%)									
		2 Adenocarcinoma	N=0 (0%)									
Milde-Langosch <i>et al.</i> (1995), Germany	MY09/11 (HPV6/11, 16, 18, 31, 33, 35)	34 Keratinizing 6 Basaloid	N=8 (23.5%) N=3 (50%)	N=0 (0%)	N=0 (0%)	N=10 (90.1%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=1 (9.1%) (HPVx)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.

Table 2.7. Prevalence of HPV DNA in case series of vulvar cancer (10 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Pilotti <i>et al.</i> (1995), Italy	ISH/SBH/PCR for HPV 6, 11, 16 & 18	13 Bowenoid SCC	N=13 (100%)	N=0 (0%)	N=0 (0%)	N=13 (100%)	N=0 (0%)	N/A	N/A	N/A	N/A	Bouin or formalin-fixed paraffin-embedded tissue samples.
		16 Keratinizing SCC	N=4 (25%)	N=0 (0%)	N=0 (0%)	N=3 (75%)	N=1 (25%)	N/A	N/A	N/A	N/A	
Nagano <i>et al.</i> (1996), Japan	L1-PCR (L1C1 and L1C2) for HPV6, 11, 16, 18, 30, 31, 33, 34, 35, 39, 42, 45, 51, 52, 53, 56 and 58	11	N=8 (72.7%)	N=1 (12.5%)	N=0 (0%)	N=4 (50%)	N=1 (12.5%)	N=0 (0%)	N=0 (0%)	N=1 (12.5%) (HPV51) N=1 (12.5%) (HPV56)	N=0 (0%)	Frozen samples.
Guo <i>et al.</i> (1996), China	PCR HPV6/11, 16, 18	24 Keratinizing	N=0 (0%)	N=0 (0%)		N=0 (0%)	N=0 (0%)	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
		7 Basaloid	N=5 (71.4%)	N=1 (20%)		N=4 (80%)	N=0 (0%)	N/A	N/A	N/A	N/A	
		6 Warty	N=5 (83.3%)	N=2 (40%)		N=3 (60%)	N=0 (0%)	N/A	N/A	N/A	N/A	
Trimble <i>et al.</i> (1996), USA	ISH for 6/11/16/18/31/33/35/42/43/44/45/51/52/56	21 basaloid-warty (81% VIN associated)	N=18 (85.7%)	N=0 (0%)	N=0 (0%)	N=49/69 (71%) (includes 21 cases + 48 cases of VIN)	N=1/69 (1.45%) (includes 21 cases + 48 cases of VIN)	N=0 (0%)	N=0 (0%)	N=19 (27.5%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		48 keratinizing (4.2% VIN associated)	N=3 (6.3%)									
Kim <i>et al.</i> (1996), USA	MY09/11 for HPV16 & HPV18, Southern Blot and type-specific for HPV6, 11, 16, 18, 31	3 Keratinizing - Poorly Differentiated	N=1 (33.3%)	N=0 (0%)	N=0 (0%)	N=1 (100%)	N=0 (0%)	N=0 (0%)	N/A	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		6 Keratinizing - Moderately Differentiated	N=1 (16.7%)	N=0 (0%)		N=1 (100%)	N=0 (0%)					
		5 Keratinizing - Well Differentiated	N=2 (40%)	N=0 (0%)		N=1 (50%)	N=1 (50%)					
		3 Basaloid	N=2 (66.7%)	N=0 (0%)		N=2 (100%)	N=0 (0%)					
		1 Warty-Verrucous	N=1 (100%)	N=1 (10%) (HPV6b)		N=0 (0%)	N=0 (0%)					
Iwasawa <i>et al.</i> (1997), Finland	MY09/11 type-specific (6, 11, 16, 18, 33)	74	N=27 (36.5%)	N=0 (0%)	N=0 (0%)	N=19 (70.4%)	N=9 (33.3%)	N/A	N=1 (3.7%)	N=1 (3.7%) (HPVx)	N=2 (7.4%) (HPV16&18) N=1 (3.7%) (HPV16&33)	Formalin-fixed paraffin-embedded tissue samples.

Table 2.7. Prevalence of HPV DNA in case series of vulvar cancer (10 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Madeleine <i>et al.</i> (1997), USA	MY09/11 (6/11, 16, 18/45, 31/33/52) or RFLP	55	N=28 (50.9%)	N=1 (3.6%)		N=24 (85.7%)	N=1 (3.6%) (HPV18/45)	N=2 (7.1%) (HPV31/33/52)		N=1 (3.6%) (HPVx)	N=1 (3.6%) (HPV16/ & other & Other)	Formalin-fixed paraffin-embedded tissue samples. histological type not specified.
Kagie <i>et al.</i> (1997), The Netherlands	CPI and CPIIG and sequencing	14 Basaloid 10 Warty 42 Keratinizing	N=4 (28.6%) N=2 (20%) N=6 (14.3%)	N/A	N/A	N=10 (83.3%)	N/A	N/A	N=1 (8.4%)	N=1 (8.4%) (HPV45)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Junge <i>et al.</i> (1997), Denmark	E6/E7 primers (16 & 33); and ISH (6/11, 16/18, 31/33)	22 Warty + Basaloid (7 recurrences) 31 Basaloid + Warty (8 recurrences) 8 Warty + Basaloid + Simple (1 recurrence)	N=13/15 recurrent (86.7%) N=37/41 non-recurrent (90.2%)	N=0 (0%)	N=0 (0%)	N=12/13 recurrent (92.3%) N=32/37 non-recurrent (86.5%)	N=0 (0%)	N=0 (0%)	N=1/13 recurrent (7.7%) N=5/37 non-recurrent (13.5%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. Includes moderate dysplasia, severe dysplasia and "in situ" carcinoma. From 16 recurrences, 5/10 (50%) were anterior region lesions of the vuvla, 2 /20 (10%) from middle region, 2/14 (14.3%) posterior region and 7/17 (41.2%) were multifocal
Gao <i>et al.</i> (1997), China	L1-PCR for HPV6/11 & HPV16/18	13	N=3 (23.1%)	N=2 (66.7%)		N=1 (33.3%)		N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
Liss J <i>et al.</i> (1998), Poland	MY09/11	18	N=3 (16.7%)	N=0 (0%)	N=0 (0%)	N=3 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Smears.
Ngan <i>et al.</i> (1999), Hong Kong	L1-PCR for HPV16 & 18	48	N=23 (47.9%)	N/A	N/A	N=18 (78.26%)	N=7 (30.4%)	N/A	N/A	N=1 (4.3%)	N=3 (13%) (HPV16&18)	Formalin-fixed paraffin-embedded tissue samples.
Pinto <i>et al.</i> (1999), Brazil	GP5+/GP6+, and HPV Type specific for 6/11, 16, 18, 45 independently, 31//33/34/35/39 and 40/42/43/44/45, and 51/52/54/56/58	122 Keratinizing 19 Basaloid 17 Warty	N=20 (16.4%) N=8 (42.1%) N=10 (58.8%)	N=2 (5.3%)		N=26 (68.4%)	N=14 (36.8%)	N=0 (0%)	N=0 (0%)	N=1 (2.6%) (HPV45)	N=4 (10.5%) (HPV16&18) N=1 (2.6%) (HPV16&6)	Formalin-fixed paraffin-embedded tissue samples.

Table 2.7. Prevalence of HPV DNA in case series of vulvar cancer (10 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Lerma <i>et al.</i> (1999), Spain	VPHFast (450-bp-long fragment of L1 region form the open reading frame) for HPV16 and 18	59 Keratinizing (Only 50 PCR)	N=3/50 (6%)	N/A	N/A	N=3 (100%)	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples. Comparison of ISCC, VIN and LS.
		1 Basaloid	N=4 (57.1%)	N/A	N/A	N=4 (100%)	N/A	N/A	N/A	N/A	N/A	
		6 Warty		N/A	N/A		N/A	N/A	N/A	N/A	N/A	
		5 Verrucous (No PCR)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Pinto <i>et al.</i> (1999), USA	PCR-RFLP MY09/11	16	N=8 (50%)	N/A	N/A	N=6 (75%)	N=0 (0%)	N=0 (0%)	N=1 (12.5%)	N=1 (12.5%) (HPVx)	N/A	Formalin-fixed paraffin-embedded tissue samples.
Menczer <i>et al.</i> (2000), Israel	E6/E7 primers for HPV16 & 18	14	N=9 (64.2%)	N/A	N/A	N=8 (88.9%)	N=1 (11.1%)	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
Abdel-Hady <i>et al.</i> (2001), UK	GP5+/6+ (6/11, 16, 18, 31, 33)	11	N=3 (27.3%)	N=0 (0%)	N=0 (0%)	N=3 (100%)	N=1 (33.3%)	N=0 (0%)	N=2 (66.7%)	N=0 (0%)	N=1 (33.3%) (HPV16&33) N=1 (33.3%) (HPV16&18&33)	Snap-Frozen samples. Histological type not specified.
Carter <i>et al.</i> (2001), USA	MY09/11 and RFLP; type-specific for 16, 18	38	N=30 (79%)	N/A	N/A	N=21 (70%)	N=1 (3.4%)	N=5 (16.7%) (HPV30/31/33/35/39)		N=3 (10%) (HPV6/45/52/54/58/66/72/73/x)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples. Patients with either a HPV16 and/or HPV18 serology result.
Al-Ghamdi <i>et al.</i> (2002), Canada	MY09/11, GP5/GP6 and type-specific for HPV16 and 18	18 keratinizing 2 basaloid 1 warty	N=17/20 (85%)	N/A	N/A	N=11 (64.7%)	N=6 (35.3%)	N/A	N/A	N=2 (11.7%)	N=2 (11.7%) (HPV16&18)	Formalin-fixed paraffin-embedded tissue samples.. 2 immunocompromised patients.
Gasco <i>et al.</i> (2002), UK	MY09/11, CPI/IIG	36	N=13 (36.1%)	N/A	N/A	N=13 (100%)	N/A	N/A	N/A	N/A	N/A	Snap frozen samples.
Allen <i>et al.</i> (2002), Australia	MY09/11 and Type-specific for 6, 11, 16, 18, 31, 33, 35, 39, 45, 51 & 52	18	N=10 (55.6%)	N=0 (0%)	N=0 (0%)	N=10 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Koyamatsu <i>et al.</i> (2003), Japan	E7 (115-158 bp) for HPV16, HPV 18, L1 (250bp) for HPV 6,11,16,18,31,33, 42,52,58	31	N=4 (13%)	N/A	N/A	N=2 (50%)	N=2 (50%)	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.

Table 2.7. Prevalence of HPV DNA in case series of vulvar cancer (10 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Bryndorf <i>et al.</i> (2004), Denmark	SPF-PCR (LiPA), HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74	10	N=6 (60%)	N=0 (0%)	N=0 (0%)	N=4 (66.7%)	N=0 (0%)	N=0 (0%)	N=2 (33.3%)	N=1 (16.7%) (HPV56)	N=1 (16.7%) (HPV16&33)	Formalin-fixed paraffin-embedded tissue samples.
Pinto <i>et al.</i> (2004), Brazil	GP5+/GP6+, and HPV Type specific for 6/11, 16, 18, 45, 31//33/34/35/39 and 40/42/43/44/45, and 51/52/54/56/58	161	N=39 (24.2%)	N=2 (5.1%)		N=26 (66.7%)	N=15 (38.4%)	N=0 (0%)	N=0 (0%)	N=1 (2.6%) (HPV45)	N=4 (10.3%) (HPV16&18) N=1 (2.6%) (HPV16&6/11)	Formalin-fixed paraffin-embedded tissue samples.
Bonvicini <i>et al.</i> (2005), Italy	ISH/MY09/11	16 Keratinizing (Differentiated)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Santos <i>et al.</i> (2006), Spain	GP5+/GP6+ & SPF10; INNO-LIPA	11 Basaloid SCC	N=7 (63.6%)	N=0 (0%)	N=0 (0%)	N=5 (71.4%)	N=0 (0%)	N=0 (0%)	N=2 (28.6%)	N=0 (0%)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		6 Warty SCC	N=3 (50%)	N=0 (0%)	N=0 (0%)	N=1 (33.3%)	N=0 (0%)	N=0 (0%)	N=1 (33.3%)	N=1 (33.3%) (HPV51)	N=0 (0%)	
		75 Keratinizing SCC	N=6 (8%)	N=2 (33.3%)	N=0 (0%)	N=6 (100%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=0 (0%)	N=2 (33.3%) (HPV6&16)	
Knopp <i>et al.</i> (2006), Norway	ISH for 16, 18, 31, 33	198 Keratinizing	N=35 (17.7%)	N/A	N/A	N=43 (91.5%)	N=2 (4.25%)	N=0 (0%)	N=2 (4.25%)	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.
		14 Basaloid	N=10.4 (71%)									
		5 Verrucous	N=2 (40%)									
Hampl <i>et al.</i> (2006), Germany	MY09/11, GP5+/GP6+ and type-specific for HPV6, 11, 16, 18, 31, 33, 35, 40, 42, 44, 45, 51, 52, 53, 55, 56, 58, 61, 66, 67, 68, 73, 74, 91, IS887/MM4 and HPV18	48	N=29 (60.4%)	N=2 (6.9%)		N=19 (65.5%)	N=1 (3.5%)	N=2 (6.9%)	N=4 (13.8%)	N=1 (3.5%) (HPVx)	N=4 (13.8%)	Formalin-fixed paraffin-embedded tissue samples. 2 patients were HIV positive.
van der Avoort <i>et al.</i> (2006), The Netherlands	SPF-PCR (LiPA), HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74	9 SCC Well-differentiated 5 SCC Moderately differentiated 2 SCC Poorly differentiated	N=0 (0%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Formalin-fixed paraffin-embedded tissue samples.

Table 2.7. Prevalence of HPV DNA in case series of vulvar cancer (10 cases)

Reference, study location	Method of detection (types included)	No. and type of lesions	Overall HPV positivity (% ^a)	Type-specific HPV positivity (% ^b)							Multiple infections (%)	Comments
				6	11	16	18	31	33	Others (type)		
Osakabe <i>et al.</i> (2007), Japan	PCR-RFLP (6, 11, 16, 18, 31, 33, 42, 52, 58)	13 Keratinizing	N=0 (0%)	N=0 (0%)	N=0 (0%)	N/A	N=0 (0%)	N=0 (0%)	N=0 (0%)	N/A	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
		3 Non-Keratinizing										
		1 Basaloid	N=1 (100%)	N=0 (0%)		N=1 (100%)				N=0 (0%)		
		3 Warty	N=3 (100%)	N=0 (0%)		N=2 (66%)				N=1 (33%) (HPV52)		
		1 Verrucous	N=1 (100%)	N=1 (100%)		N=0 (0%)				N=0 (0%)		
Skapa <i>et al.</i> (2007), Czech republic	GP5+/GP6+	69	N=29 (42%)	N=1 (3.4%)	N=0 (0%)	N=19 (65.5%)	N=0 (0%)	N=0 (0%)	N=6 (20.7%)	N=1 (3.4%) (HPV42) N=2 (6.9%) (HPV45)	N=0 (0%)	Formalin-fixed paraffin-embedded tissue samples.
Hampl <i>et al.</i> (2008), Germany	MY09/11, GP5/GP6 and type-specific for HPV6, 11, 16, 18, 31, 33, 35, 40, 42, 44, 45, 51, 52, 53, 55, 56, 58, 61, 66, 67, 68, 73, 74, 91, IS887/MM4 and HPV1A18	36	N=18 (50%)	N=1 (5.6%)	N=1 (5.6%) (HPV6&11)	N=11 (61.1%)	N=1 (5.6%)	N=0 (0%)	N=2 (11.1%)	N=1 (5.6%) (HPV52) N=1 (5.6%) (HPV55) N=1 (5.6%) (HPV42)	N=1 (5.6%) (HPV16&33)	Formalin-fixed paraffin-embedded tissue samples.
Sutton <i>et al.</i> (2008), USA	PCR with Linear Array HPV for HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, CP6108	71 Conventional-NOS	N=44 (62%)	N=1 (1.23%)	N=0 (0%)	N=65 (80.2%)	N=2 (2.5%)	N=0 (0%)	N=12 (14.8%)	N=4 (4.9%) (HPV45) N=3 (3.7%) (HPV52) N=1 (1.23%) (HPV26) N=1 (1.23%) (HPV53) N=1 (1.23%) (HPV61) N=1 (1.23%) (HPV62) N=1 (1.23%) (HPV67) N=1 (1.23%) (HPV84)	N=5 (6.2%) (HPV16&33) N=2 (2.5%) (HPV16&6) N=1 (1.23%) (HPV16&45) N=1 (1.23%) (HPV16&53) N=1 (1.23%) (HPV16&62) N=1 (1.23%) (HPV16&67) N=1 (1.23%) (HPV33&84) N=1 (1.23%) (HPV16&33&53) N=1 (1.23%) (HPV45&52&62)	Formalin-fixed paraffin-embedded tissue samples.
		35 Warty 10 Basaloid	N=30 (85.7%) N=7 (70%)									

a. percentages given are percentages of HPV positives among all samples.

b. percentages given are percentages of HPV types among HPV positives cases.